Skip to main content
. 2013 Jul;15(7):749–760. doi: 10.1593/neo.121956

Figure 2.

Figure 2

Sh3gl2 loss in bladder cancer correlates with tumor progression. (A) Analysis of three independent cohorts of bladder cancer specimens (i–iii) using the Oncomine database revealed decreased Sh3gl2 mRNA levels in both superficial and invasive lesions compared to normal bladder tissue. (B) IHC analysis of a bladder cancer tissue microarray (TMA) revealed a marked decrease in Sh3gl2 expression in cancer tissues versus noncancerous tissues, as well as a trend toward decreased expression in high-grade versus low-grade cancers. Representative images of Sh3gl2 staining in low- and high-grade lesions are presented in a and b; c represents the control receiving no primary antibody. Original magnification, x200. (C) Representative staining of (a) benign, (b) low-grade, and (c) high-grade lesions on a bladder cancer progression TMA. Original magnification, x200. (D) Quantification of IHC staining of a bladder cancer progression array revealed frequent and progressive loss of Sh3gl2. Graphs show the proportion of tissue specimens (%) in each subgroup with low (-/+) versus high (++/+++) intensity staining for Sh3gl2 protein. Sh3gl2 staining intensity was significantly lower in (i) malignant versus benign specimens (P < .001), (ii) in high-grade (G3) versus low-grade (G1/G2) specimens (P < .001), and (iii) in muscle-invasive versus non-muscle-invasive specimens (P = .03), as well as non-muscle-invasive versus benign specimens (P <.001).